Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.
Scottish Inflammatory Prognostic Score (SIPS)
biomarker
immune checkpoint inhibitors
inflammation
non-small-cell lung cancer (NSCLC)
prognosis
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
08
11
2021
revised:
21
01
2022
accepted:
09
02
2022
pubmed:
11
4
2022
medline:
4
5
2022
entrez:
10
4
2022
Statut:
ppublish
Résumé
Pembrolizumab is an established first-line option for patients with advanced non-small-cell lung cancer (NSCLC) expressing programmed death-ligand 1 ≥50%. Durable responses are seen in a subset of patients; however, many derive little clinical benefit. Biomarkers of the systemic inflammatory response predict survival in NSCLC. We evaluated their prognostic significance in patients receiving first-line pembrolizumab for advanced NSCLC. Patients treated with first-line pembrolizumab for advanced NSCLC with programmed death-ligand 1 expression ≥50% at two regional Scottish cancer centres were identified. Pretreatment inflammatory biomarkers (white cell count, neutrophil count, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, albumin, prognostic nutritional index) were recorded. The relationship between these and progression-free survival (PFS) and overall survival (OS) were examined. Data were available for 219 patients. On multivariate analysis, albumin and neutrophil count were independently associated with PFS (P < 0.001, P = 0.002, respectively) and OS (both P < 0.001). A simple score combining these biomarkers was explored. The Scottish Inflammatory Prognostic Score (SIPS) assigned 1 point each for albumin <35 g/l and neutrophil count >7.5 × 10 SIPS, a simple score combining albumin and neutrophil count, predicts survival in patients with NSCLC receiving first-line pembrolizumab. Unlike many proposed prognostic scores, SIPS uses only routinely collected pretreatment test results and provides a categorical score. It stratifies survival across clinically meaningful time periods that may assist clinicians and patients with treatment decisions. We advocate validation of the prognostic utility of SIPS in this and other immune checkpoint inhibitor treatment settings.
Identifiants
pubmed: 35398717
pii: S2059-7029(22)00061-8
doi: 10.1016/j.esmoop.2022.100445
pmc: PMC9058907
pii:
doi:
Substances chimiques
Albumins
0
Biomarkers
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100445Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Clin Cancer Res. 2013 Oct 1;19(19):5456-64
pubmed: 23938289
Front Oncol. 2020 Oct 09;10:572853
pubmed: 33163403
BMC Cancer. 2020 Dec 3;20(1):1185
pubmed: 33272262
Biomark Res. 2020 Aug 26;8:34
pubmed: 32864131
Int J Colorectal Dis. 2019 Jul;34(7):1303-1315
pubmed: 31177316
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
BMJ Open. 2015 Apr 08;5(4):e006404
pubmed: 25854964
Transl Lung Cancer Res. 2019 Jun;8(3):214-226
pubmed: 31367535
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Clin Oncol (R Coll Radiol). 2020 Sep;32(9):553-561
pubmed: 32684503
PLoS One. 2018 Jan 3;13(1):e0190410
pubmed: 29298330
Immunol Rev. 2016 Sep;273(1):312-28
pubmed: 27558343
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Eur J Cancer. 2009 Jul;45(11):1950-8
pubmed: 19231158
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Cancer. 2021 Mar 15;12(10):2960-2967
pubmed: 33854596
Br J Cancer. 2018 Jul;119(1):40-51
pubmed: 29789606
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Oncol. 2021 Mar 20;39(9):1020-1028
pubmed: 33529051
Br J Cancer. 2007 Nov 5;97(9):1266-70
pubmed: 17923866
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
JAMA Oncol. 2018 Mar 01;4(3):351-357
pubmed: 29327044
Lung Cancer. 2015 Jun;88(3):304-9
pubmed: 25870155
PLoS One. 2014 Aug 22;9(8):e105983
pubmed: 25148079
Oncologist. 2019 Sep;24(9):e960-e967
pubmed: 30975922
Clin Lung Cancer. 2018 Sep;19(5):426-434.e1
pubmed: 29803574
Medicine (Baltimore). 2019 Jan;98(3):e13788
pubmed: 30653090
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Biosci Trends. 2020 Mar 16;14(1):48-55
pubmed: 32023563
Clin Lung Cancer. 2020 Sep;21(5):e366-e379
pubmed: 32199806
Br J Cancer. 2001 Nov 30;85(11):1634-9
pubmed: 11742480
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33219093
Sci Rep. 2021 Mar 18;11(1):6306
pubmed: 33737641
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Transl Lung Cancer Res. 2021 Mar;10(3):1397-1407
pubmed: 33889518
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Dis Markers. 2020 Apr 21;2020:1371964
pubmed: 32377267
Ann Transl Med. 2019 Oct;7(20):572
pubmed: 31807553
BMC Med. 2016 May 05;14:73
pubmed: 27151159
J Thorac Dis. 2018 Sep;10(9):5298-5307
pubmed: 30416777
Semin Dial. 2004 Nov-Dec;17(6):432-7
pubmed: 15660573
J Clin Oncol. 2016 Aug 10;34(23):2769-75
pubmed: 27354484
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
BMC Urol. 2020 Jul 6;20(1):90
pubmed: 32631294
Oncologist. 2016 May;21(5):634-42
pubmed: 26984449
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
J Thorac Dis. 2020 Apr;12(4):1520-1528
pubmed: 32395289
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Crit Rev Oncol Hematol. 2018 Dec;132:130-137
pubmed: 30447918
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
Nutr J. 2010 Dec 22;9:69
pubmed: 21176210
Transl Lung Cancer Res. 2021 Jan;10(1):355-367
pubmed: 33569318
Cancer Treat Rev. 2013 Aug;39(5):534-40
pubmed: 22995477
BMJ Open. 2020 Jun 3;10(6):e035031
pubmed: 32499266
ESMO Open. 2021 Oct;6(5):100254
pubmed: 34481329
Curr Oncol. 2018 Oct;25(5):e373-e384
pubmed: 30464687
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32753547
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Sci Rep. 2016 Mar 30;6:23893
pubmed: 27025911